Idioma:

Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries

Baim, Donald S. ; Cutlip, Donald E. ; Midei, Mark ; Linnemeier, Thomas J. ; Schreiber, Theodore ; Cox, David ; Kereiakes, Dean ; Popma, Jeffrey J. ; Robertson, Linda ; Prince, Rebecca ; Lansky, Alexandra J. ; Ho, Kalon K.L. ; Kuntz, Richard E.

The American journal of cardiology, 2001-01, Vol.87 (2), p.157-162 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries
Autor: Baim, Donald S. ; Cutlip, Donald E. ; Midei, Mark ; Linnemeier, Thomas J. ; Schreiber, Theodore ; Cox, David ; Kereiakes, Dean ; Popma, Jeffrey J. ; Robertson, Linda ; Prince, Rebecca ; Lansky, Alexandra J. ; Ho, Kalon K.L. ; Kuntz, Richard E.
Assuntos: Aged ; Angioplasty ; Angioplasty, Balloon, Coronary ; Biological and medical sciences ; Clinical outcomes ; Clinical trials ; Coronary Angiography ; Coronary Disease - therapy ; Diseases of the cardiovascular system ; Female ; Humans ; Male ; Medical sciences ; Medical supplies ; Middle Aged ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Recurrence ; Regression Analysis ; Stents ; Survival Analysis ; Treatment Outcome
É parte de: The American journal of cardiology, 2001-01, Vol.87 (2), p.157-162
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: The MULTI-LINK (ML) stent is a novel second generation coronary stent. The ACS MultiLink Stent Clinical Equivalence in De Novo Lesions Trial (ASCENT) randomized 1,040 patients with single, de novo native vessel lesions to treatment with the ML stent or the benchmark Palmaz-Schatz (PS) stent, to demonstrate that the ML stent was not inferior to (i.e., equivalent or better than) the PS stent in terms of target vessel failure by 9 months. Successful stent delivery was achieved in 98.8% versus 96.9% of patients, with a slightly lower postprocedural diameter stenosis (8% vs 10%, p = 0.04), and no difference in 30-day major adverse cardiac events (5.0% vs 6.5%) for the ML stent versus the PS stent. The primary end point of target vessel failure at 9 months was seen in 15.1% of ML-treated patients versus 16.7% of PS-treated patients, with the ML proving to be equal or superior to the PS stent (p <0.001 by test for equivalency). In a prespecified subset, angiographic restudy showed a nonsignificant trend for reduced ML restenosis (16.0% vs 22.1%). Thus, the ML stent showed excellent deliverability and acute results, with 9-month clinical and 6-month angiographic outcomes that were equivalent or better than the PS stent.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries

Baim, Donald S. ; Cutlip, Donald E. ; Midei, Mark ; Linnemeier, Thomas J. ; Schreiber, Theodore ; Cox, David ; Kereiakes, Dean ; Popma, Jeffrey J. ; Robertson, Linda ; Prince, Rebecca ; Lansky, Alexandra J. ; Ho, Kalon K.L. ; Kuntz, Richard E.

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.